

# VOLUME 30 1988

## SUBJECT INDEX

- Acquisition, 949  
 retention  
 scopolamine  
 T-maze, 14-unit
- Active avoidance, 77  
 aminergic neurotransmitter systems  
 memory retrieval  
 pharmacological stimulation
- Activity meter, 199  
 motor development  
 nicotine  
 prenatal changes
- Acute administration  
 amphetamine, 871  
 behavioral effects, 809  
 caffeine, 809  
 chronic administration, 809  
 ethanol, 769  
 latent inhibition disruption, 871  
 MHPG-SO<sub>4</sub>, 769  
 noradrenaline metabolism, 769  
 strain differences, 769
- Acute effects, 737  
 behavioral tolerance  
 chronic effects  
 cocaine  
 complex operant behavior  
 dose-dependent effects  
 monkeys
- Acute pretreatment, 1065  
 nicotine  
 plasma corticosterone levels  
 strain differences
- Acute response, 269  
 genetic influence  
 nicotine  
 nicotine tolerance
- Adenosine, 155  
 cerebellum  
 ethanol  
 motor incoordination  
 spontaneous motor activity inhibition
- Adenosine receptor downregulation, 303  
 brain, rat  
 chronic administration  
 diazepam
- Adenosine receptors, 707  
 autoradiography  
 methylxanthines  
 strain differences
- Ad lib feeding, 649  
 body weight restriction  
 dorsomedial hypothalamic nucleus  
 food restriction  
 lesions, dorsomedial hypothalamic nucleus
- Adrenalectomy  
 analgesia, stress-induced, 791  
 corticosterone, 101  
 H<sub>2</sub>-receptor, 791  
 hypophysectomy, 791  
 schedule-induced wheel running, 101
- (1-24)Adrenocorticotrophic hormone, 391  
 atria, rat  
<sup>3</sup>H-norepinephrine uptake
- Aggression, 409  
 carbamazepine  
 cats  
 midbrain periaqueductal gray
- Aggressive behavior  
 alphaxalone, 729  
 comparative effects, 729  
 locomotor behavior, 729  
 medroxyprogesterone acetate, 829  
 mice, male, 829  
 progesterone, 729  
 reproductive behavior, 729  
 tamoxifen, 829
- Alcohol intake, 823  
 renin-angiotensin system  
 serotonin uptake inhibitor
- N-Allylnormetazocine, 493  
 oral self-administration  
 phencyclidine  
 rhesus monkeys  
 withdrawal
- Alpha-adrenoceptors, 471  
 biphasic effects  
 clonidine  
 conflict behavior
- Alphaxalone, 729  
 aggressive behavior  
 comparative effects  
 locomotor behavior  
 progesterone  
 reproductive behavior
- Alprazolam, 511  
 low-dose administration  
 motor activity
- Aminergic neurotransmitter systems, 77  
 active avoidance  
 memory retrieval  
 pharmacological stimulation
- $\alpha$ -Amino-3-hydroxy-5-methylisoxazole-4-propionate, 379  
 hypermotility  
 nucleus accumbens  
 quisqualic acid receptors
- Amnesia  
 MK-801,205  
 retrieval, 1093  
 scopolamine, 1093
- Amphetamine  
 acute administration, 871  
 amphetamine anorexia, 641  
 anorectic effects, 755  
 behavioral microanalysis, 641  
 cholecystokinin-octapeptide, 309  
 chronic administration, 899  
 circadian rhythm, 535  
 continuous administration, 535  
 dopamine, 641  
 drug interactions, 641  
 EEG power spectra, 489  
 hyperlocomotion, 309  
 intra-accumbens injection, 309  
 intracerebroventricular injection, 309  
 latent inhibition disruption, 871  
 locomotor behavior, 535  
 motor activity, 489  
 opiate mechanisms, 755  
 route of administration, 309  
 stereotypy, 309, 535, 899  
 tolerance development, 755  
 U50488H, 755
- d-Amphetamine  
 $\gamma$ -butyrolactone, 45  
 CGS 10746B, 1089  
 conditioned place preference, 853  
 diazepam, 853  
 drug discrimination, 1085, 1089  
 drug interactions, 45, 853  
 lever pressing, 45  
 morphine, 853  
 naloxone, 45  
 nisoxetine, 1085  
 ritanserin, 853
- Amphetamine anorexia, 641  
 amphetamine  
 behavioral microanalysis  
 dopamine  
 drug interactions
- Analepsis, 115  
 codeine  
 rat/rabbit comparisons
- Analgesia  
 bremazocine, 817  
 ethylketocyclazocine, 817  
 intestinal inhibition, 319  
 morphine, 123, 319  
 neonatal administration, 817  
 prenatal stress, 123  
 sex differences, 123  
 supraspinal cerebral areas, 319
- Analgesia, morphine-induced, 905  
 jumping, naloxone-induced  
 morphine  
 naloxone  
 restraint
- Analgesia, stress-induced, 791  
 adrenalectomy  
 H<sub>2</sub>-receptor  
 hypophysectomy
- Anatomical analysis, 129  
 carbachol  
 frontal cortex  
 motor seizures
- Angiotensins, 343  
 blood pressure responsiveness  
 genetic breeding  
 intracarotid infusion
- Anorectic effects, 755  
 amphetamine  
 opiate mechanisms  
 tolerance development  
 U50488H

- Anorexia, 89
  - dexfenfluramine
  - ischymetric mechanisms
  - lipostatic mechanisms
  - metabolic chamber
- Antagonist treatment, 443
  - heroin
  - intravenous self-administration
  - nucleus accumbens
  - periaqueductal grey
- Antinociception, 65
  - bradycardia
  - hypotension
  - intrathecal antagonists
  - intravenous administration
  - [D-Ala<sup>2</sup>]-methionine enkephalinamide
- Anxiety, 701
  - benzodiazepine receptors
  - drug interactions
  - ethanol
  - plus-maze test
- Anxiogenic effects, 331
  - benzodiazepine receptors
  - brain, rat
  - N-butyl  $\beta$  carboline-3-carboxylate
  - proconvulsant effects
- Anxiolytic identification, 775
  - conditioned defensive burying
- Anxiolytics, 1071
  - bupirone
  - chlordiazepoxide
  - defensive burying
  - drug comparisons
  - shock-probe test
- Apomorphine
  - body temperature, 683
  - climbing behavior, 143
  - dose-dependent effects, 107
  - genetic analysis, 143
  - haloperidol, 683
  - locomotor behavior, 143
  - passive avoidance learning, 107
  - punished responding, 753
  - SCH 23390, 683
  - unpunished responding, 753
- Apparatus
  - eight-arm radial maze, 119
  - metabolic chamber, 89
  - Morris Water Maze, 519
  - osmotic mini-pump, 357
  - T-maze, 14-unit, 949
- Approach response, 397
  - differential effects
  - electrical stimulation
  - escape response
  - intracerebral microinjection
  - lateral hypothalamus
  - morphine
- Asymmetrical activation, 911
  - cerebral cortex
  - GABA-gated chloride channels
- Atria, rat, 391
  - (1-24)adrenocorticotrophic hormone
  - <sup>3</sup>H-norepinephrine uptake
- Atropine, 625
  - chickens
  - immobility response
  - scopolamine
  - strain differences
- Auditory stimulus, 983
  - functional neuroanatomy
  - heroin
- Autoradiography
  - adenosine receptors, 707
  - brain regional uptake, 781
  - 2-deoxyglucose, 781
  - ethanol, 781
  - methylxanthines, 707
  - strain differences, 707, 781
- Aversive effects, 693
  - dopamine innervation
  - lesions, 6-OHDA
  - opiates
  - visceral cortex
- Behavioral effects
  - acute administration, 809
  - caffeine, 809
  - chronic administration, 809
  - 5-methoxytryptamine, 847
  - parachlorophenylalanine, 847
  - prenatal exposure, 847
  - serotonin uptake, 847
  - thyrotropin-releasing hormone
    - binding, 73
  - triazolobenzodiazepines, 73
- Behavioral/electrocorticographic comparisons, 479
  - diazepam
  - drug interactions
  - pentylene-tetrazol
  - rat pups
- Behavioral microanalysis, 641
  - amphetamine
  - amphetamine anorexia
  - dopamine
  - drug interactions
- Behavioral tolerance, 737
  - acute effects
  - chronic effects
  - cocaine
  - complex operant behavior
  - dose-dependent effects
  - monkeys
- Benzodiazepine binding sites, 679
  - in vitro autoradiography
  - substantia innominata
- Benzodiazepine receptor binding affinity, 665
  - 3-hydroxykynurenine
  - neonatal deficiency
  - seizures
  - vitamin B-6
- Benzodiazepine receptors
  - anxiety, 701
  - anxiogenic effects, 331
  - brain, rat, 331
  - N-butyl  $\beta$  carboline-3-carboxylate, 331
  - drug interactions, 701
  - ethanol, 701
  - plus-maze test, 701
  - proconvulsant effects, 331
- Benzodiazepines
  - chlordiazepoxide, 515
  - hunger-mimetic model, 515
  - hyperphagia, 515
  - postdecapitation convulsions, 1101
  - tonic component, 1001
- Bicuculline, 337
  - flight behavior
  - microinjection
  - rats, detelencephalated
  - semicarbazide
- Binding characteristics, 255
  - nicotinic ligands
  - pharmacologic analysis
- Biodisposition, 371
  - charcoal
  - phencyclidine
- Biogenic amines, 795
  - discrete brain regions
  - high performance liquid chromatography
- Biphasic effects, 471
  - alpha-adrenoceptors
  - clonidine
  - conflict behavior
- Blood pressure responsiveness, 343
  - angiotensins
  - genetic breeding
  - intracarotid infusion
- Body temperature
  - apomorphine, 683
  - cannabidiol, 675
  - cannabinol, 675
  - chronic treatment, 451
  - dose-dependent effects, 451
  - drug interactions, 451, 675
  - haloperidol, 683
  - 8-OH-DPAT, 451
  - open-field activity, 675
  - SCH 23390, 683
- Body weight restriction, 649
  - ad lib feeding
  - dorsomedial hypothalamic nucleus
  - food restriction
  - lesions, dorsomedial hypothalamic nucleus
- Bradycardia, 65
  - antinociception
  - hypotension
  - intrathecal antagonists
  - intravenous administration
  - [D-Ala<sup>2</sup>]-methionine enkephalinamide
- Brain
  - amygdala, 129, 319, 769
  - brain stem, 137
  - bulbar reticular formation, 319
  - caudate, 319
  - caudate-putamen, 325
  - cerebellum, 155
  - cerebral cortex, 137, 669, 769, 911, 941
  - dorsal hypothalamus, 319
  - dorsal noradrenergic bundle, 835
  - dorsal periaqueductal gray, 337
  - dorsomedial hypothalamic nucleus, 649
  - frontal cortex, 129, 319
  - hippocampus, 117, 769
  - hypothalamic paraventricular nucleus, 925
  - hypothalamus, 769, 941
  - lateral hypothalamus, 319, 365, 397, 657, 917
  - lateral ventricle, 519
  - locus coeruleus, 13, 769
  - midbrain, 941
  - medial anterior cortex, 129
  - medial forebrain bundle-lateral hypothalamus, 195
  - medial hypothalamus, 337
  - median raphe nucleus, 529, 577
  - midbrain periaqueductal gray, 409
  - mid-line thalamus, 319
  - nucleus accumbens, 189, 309, 379, 443, 1051

nucleus basalis of Meynert, 129  
periaqueductal gray, 319, 443  
raphe magnus nucleus, 319  
striatum, 137, 457  
ventral tegmentum, 1077  
visceral cortex, 693

Brain, rat  
adenosine receptor downregulation, 303  
anxiogenic effects, 331  
benzodiazepine receptors, 331  
N-butyl  $\beta$  carboline-3-carboxylate, 331  
chronic administration, 303  
diazepam, 303  
hypothermia, 941  
proconvulsant effects, 331  
thyrotropin-releasing hormone, 941

Brain regional uptake, 781  
autoradiography  
2-deoxyglucose  
ethanol  
strain differences

Brain-stimulation reward, 195  
buprenorphine  
reinforcing properties  
reward threshold

Bremazocine, 817  
analgesia  
ethylketocyclazocine  
neonatal administration

4-Bromo-2,5-dimethoxyphenethylamine, 597  
drugs of abuse

Buprenorphine  
brain-stimulation reward, 195  
differential tolerance, 977  
diprenorphine, 977  
drug comparisons, 977  
food intake, 977  
heroin, 977  
monkeys, 977  
reinforcing properties, 195  
reward threshold, 195

Buspirone  
anxiolytics, 1071  
chlordiazepoxide, 1071  
defensive burying, 1071  
drug comparisons, 1071  
gepirone, 723  
8-hydroxy-2-(di-n-propylamino)tetralin, 723  
pigeons, 723  
shock-probe test, 1071  
unpunished responding, 723

N-Butyl  $\beta$  carboline-3-carboxylate, 331  
anxiogenic effects  
benzodiazepine receptors  
brain, rat  
proconvulsant effects

$\gamma$ -Butyrolactone, 45  
d-amphetamine  
drug interactions  
lever pressing  
naloxone

Caffeine, 809  
acute administration  
behavioral effects  
chronic administration

Cannabidiol, 675  
body temperature  
cannabinol  
drug interactions  
open-field activity

Cannabinol, 675  
body temperature  
cannabidiol  
drug interactions  
open-field activity

Carbachol, 129  
anatomical analysis  
frontal cortex  
motor seizures

Carbamate esters, 403  
nicotine  
nicotine agonists  
nicotine antagonists  
structure-activity studies

Carbamazepine, 409  
aggression  
cats  
midbrain periaqueductal gray

$\beta$ -Carbolines, 351  
drug discrimination  
FG 7142  
footshock  
novel environment

Catalepsy, 765  
dopamine receptor  
dose-dependent effects  
drug interactions  
LY7155

Catecholamines, 589  
drug interactions  
endogenous opioids  
self-stimulation reward  
ventral tegmental area

Cats  
aggression, 409  
carbamazepine, 409  
midbrain periaqueductal gray, 409  
naloxone, 543  
penile erection, 543

Central benzodiazepine agonist, 749  
clonazepam  
drug comparisons  
NaCl intake  
peripheral benzodiazepine agonist  
RO 5-4864

Central nicotinic receptors, 235  
conditioned taste aversion  
discriminative stimulus  
nicotine

Cerebellum, 155  
adenosine  
ethanol  
motor incoordination  
spontaneous motor activity inhibition

Cerebral cortex, 911  
asymmetrical activation  
GABA-gated chloride channels

Cerebral depletion, 137  
conditioned avoidance responding  
norepinephrine

CGS 10746B, 1089  
d-amphetamine  
drug discrimination

Charcoal, 371  
biodisposition  
phencyclidine

Chemoconvulsants, 995  
drug interactions  
GABAergic drugs  
pentobarbital  
phenobarbital

Chickens, 625  
atropine  
immobility response  
scopolamine  
strain differences

Chlordiazepoxide  
anxiolytics, 1071  
benzodiazepines, 515  
buspirone, 1071  
chronic intake, 385  
contextual fear, 209  
cross-tolerance, 385  
defensive burying, 1071  
drug comparisons, 1071  
ethanol, 385  
ethanol tolerance, 385  
hunger-mimetic model, 515  
hyperphagia, 515  
nociception, 209  
shock controllability, 209  
shock-probe test, 1071

Cholecystokinin, 569  
dose-dependent effects  
rate-decreasing effects  
schedule-controlled behavior

Cholecystokinin-octapeptide, 309  
amphetamine  
hyperlocomotion  
intra-accumbens injection  
intracerebroventricular injection  
route of administration  
stereotypy

Chronic administration  
acute administration, 809  
adenosine receptor downregulation, 303  
amphetamine, 899  
behavioral effects, 809  
brain, rat, 303  
caffeine, 809  
clorgyline, 299  
desmethylimipramine, 299  
diazepam, 303  
l-dopa, 585  
drinking, 299  
eating, 299  
haloperidol, 585  
rebound enhancement, 585  
self-stimulation, 585  
stereotyped behavior, 899

Chronic effects, 737  
acute effects  
behavioral tolerance  
cocaine  
complex operant behavior  
dose-dependent effects  
monkeys

Chronic intake, 385  
chlordiazepoxide  
cross-tolerance  
ethanol  
ethanol tolerance

Chronic stress, 169  
 $[^3\text{H}]$ cyclohexyladenosine  
hypothalamus  
receptor ligand binding

Chronic treatment, 451  
body temperature  
dose-dependent effects  
drug interactions  
8-OH-DPAT

- Circadian rhythm, 535
  - amphetamine
  - continuous administration
  - locomotor behavior
  - stereotypy
- Circadian studies, 347
  - clorgyline
  - 5-hydroxytryptamine receptors
- Circling behavior, 1077
  - dopaminergic uptake blocker
  - morphine
- Citalopram, 613
  - discriminative stimulus
  - drug comparisons
  - l-5-hydroxytryptophan
  - RO 4-4620
- Classical conditioning, 433
  - CS-UCS interval
  - d-lysergic acid diethylamide
  - reflex facilitation
- Classical trace conditioning, 427
  - d-lysergic acid diethylamide
- Clenbuterol, 417
  - investigatory behavior
  - locomotor activity
  - peripheral mediation
- Climbing behavior, 143
  - apomorphine
  - genetic analysis
  - locomotor behavior
- Clonazepam, 749
  - central benzodiazepine agonist
  - drug comparisons
  - NaCl intake
  - peripheral benzodiazepine antagonist
  - RO 5-4864
- Clonidine
  - alpha-adrenoceptors, 471
  - biphasic effects, 471
  - conflict behavior, 471
  - feeding behavior, 925
- Clorgyline
  - chronic administration, 299
  - circadian studies, 347
  - desmethylimipramine, 299
  - drinking, 299
  - eating, 299
  - 5-hydroxytryptamine receptors, 347
- Clozapine, 603
  - drug comparisons
  - fixed-consecutive-number responding
- Cocaine
  - acute effects, 737
  - behavioral tolerance, 737
  - chronic effects, 737
  - complex operant behavior, 737
  - dose-dependent effects, 737
  - imipramine, 1
  - interactive effects, 1
  - monkeys, 737
  - self-stimulation, 1
  - train-duration thresholds, 1
- Codeine, 115
  - analepsis
  - rat/rabbit comparisons
- Comparative effects, 729
  - aggressive behavior, 729
  - alphaxalone
  - locomotor behavior
  - progesterone
  - reproductive behavior
- Complex operant behavior, 737
  - acute effects
  - behavioral tolerance
  - chronic effects
  - cocaine
  - dose-dependent effects
  - monkeys
- Conditioned avoidance responding, 137
  - cerebral depletion
  - norepinephrine
- Conditioned defensive burying, 775
  - anxiolytic identification
- Conditioned place preference
  - d-amphetamine, 853
  - diazepam, 853
  - drug interactions, 853
  - hippocampus, 787
  - morphine, 787, 853
  - ritanserin, 853
- Conditioned stimulus, 859
  - cyclophosphamide
  - mice, female
  - T-cell antibody responses
  - unconditioned stimulus
- Conditioned taste aversion
  - central nicotinic receptors, 235
  - discriminative stimulus, 235
  - methylnaltrexone, 687
  - morphine, 687
  - nicotine, 235
  - opiate aversive effects, 687
  - preexposure effects, 687
- Conflict behavior, 471
  - alpha-adrenoceptors
  - biphasic effects
  - clonidine
- Contextual fear, 209
  - chlordiazepoxide
  - nociception
  - shock controllability
- Continuous administration, 535
  - amphetamine
  - circadian rhythm
  - locomotor behavior
  - stereotypy
- Continuous infusion, 357
  - embryos, chicken
  - methadone
  - opioid dependence
  - osmotic mini-pumps
- Corticosterone, 101
  - adrenalectomy
  - schedule-induced wheel running
- Corticotropin-releasing hormone, 801
  - freezing behavior
  - intracerebroventricular administration
  - pain sensitivity
- Crabs, 635
  - defensive response
  - morphine
  - naloxone
- Cross-tolerance, 385
  - chlordiazepoxide
  - chronic intake
  - ethanol
  - ethanol tolerance
- CS-UCS interval, 433
  - classical conditioning
  - d-lysergic acid diethylamide
  - reflex facilitation
- Cyclazocine, 163
  - dissociation
  - naltrexone
  - nonopioid effects
  - opioid effects
- [<sup>3</sup>H]Cyclohexyladenosine, 169
  - chronic stress
  - hypothalamus
  - receptor ligand binding
- Cyclophosphamide, 859
  - conditioned stimulus
  - mice, female
  - T-cell antibody responses
  - unconditioned stimulus
- D<sub>1</sub>/D<sub>2</sub> agonists, 457
  - dopamine
  - EEDQ
  - rotational behavior
  - selective protection
- D1/D2 dopamine receptor stimulation, 189
  - SKF 38393
  - stereotyped behaviors
- Daily running activity
  - desipramine
  - inescapable stress
  - long-term effects
- Defensive burying, 1071
  - anxiolytics
  - bupirone
  - chlordiazepoxide
  - drug comparisons
  - shock-probe test
- Defensive response, 635
  - crabs
  - morphine
  - naloxone
- 2-Deoxyglucose, 781
  - autoradiography
  - brain regional uptake
  - ethanol
  - strain differences
- Desipramine
  - daily running activity, 21
  - ethanol intake, 1045
  - fluoxetine, 1045
  - food intake, 1045
  - inescapable stress, 21
  - long-term effects, 21
  - RO 15-4513, 1045
  - strain differences, 1045
  - water intake, 1045
- Desmethylimipramine, 299
  - chronic administration
  - clorgyline
  - drinking
  - eating
- Dexfenfluramine, 89
  - anorexia
  - ischymetric mechanisms
  - lipostatic mechanisms
  - metabolic chamber
- Diazepam
  - adenosine receptor downregulation, 303
  - d-amphetamine, 853
  - behavioral/electrocorticographic comparisons, 479
  - brain, rat, 303
  - chronic administration, 303
  - conditioned place preference, 853
  - dogs, 945
  - drug interactions, 479, 853
  - flumazenil, 945
  - morphine, 853

- oral absorption, 945
- pentylentetrazol, 479
- rat pups, 479
- ritanserin, 853
- Differential effects, 397
  - approach response
  - electrical stimulation
  - escape response
  - intracerebral microinjection
  - lateral hypothalamus
  - morphine
- Differential sensitivity, 183
  - ethanol antagonism
  - RO 15-4513
  - strain differences
- Differential tolerance, 977
  - buprenorphine
  - diprenorphine
  - drug comparisons
  - food intake
  - heroin
  - monkeys
- Dihydroergocristine, 961
  - learning and memory
  - rats, aged males
- Diprenorphine, 977
  - buprenorphine
  - differential tolerance
  - drug comparisons
  - food intake
  - heroin
  - monkeys
- Discrete brain regions, 795
  - biogenic amines
  - high performance liquid chromatography
- Discriminative stimulus
  - central nicotinic receptors, 235
  - citalopram, 613
  - conditioned taste aversion, 235
  - drug comparisons, 613
  - drug interactions, 617
  - l-5-hydroxytryptophan, 613
  - LSD, 617
  - nicotine, 235
  - RO 4-46202, 613
  - serotonergic agonists, 617
  - serotonergic antagonists, 617
- Dissociation, 163
  - cyclazocine
  - naltrexone
  - nonopioid effects
  - opioid effects
- Dogs, 945
  - diazepam
  - flumazenil
  - oral absorption
- l-Dopa, 585
  - chronic administration
  - haloperidol
  - rebound enhancement
  - self-stimulation
- Dopamine
  - amphetamine, 641
  - amphetamine anorexia, 641
  - behavioral microanalysis, 641
  - D<sub>1</sub>/D<sub>2</sub> agonists, 457
  - drug interactions, 641
  - EEDQ, 457
  - hyperactivity, 577
  - lateral hypothalamus, 365
  - median raphe nucleus, 577
  - morphine, 577
  - neonatal depletions, 365
  - rats, adult, 365
  - rotational behavior, 457
  - selective protection, 457
  - stimulation reward, 365
- Dopamine D-1 receptors, 325
  - dopamine D-2 receptors
  - receptor density
  - receptor distribution
  - strain differences
- Dopamine D-2 receptors, 325
  - dopamine D-1 receptors
  - receptor density
  - receptor distribution
  - strain differences
- Dopamine innervation, 693
  - aversive effects
  - lesions, 6-OHDA
  - opiates
  - visceral cortex
- Dopamine-mediated behavior, 463
  - drug comparisons
- Dopamine receptors
  - catalepsy, 765
  - dose-dependent effects, 765
  - drug discrimination, 55
  - drug interactions, 55, 765
  - environment-specific conditioning, 525
  - ethanol, 55
  - LY17155, 765
  - quinpirole, 525
  - serotonin receptors, 55
- Dopaminergic uptake blocker, 1077
  - circling behavior
  - morphine
- Dorsal noradrenergic bundle, 835
  - learning
  - lesions, 6-hydroxydopamine
  - memory
- Dorsomedial hypothalamic nucleus, 649
  - ad lib feeding
  - body weight restriction
  - food restriction
  - lesions, dorsomedial hypothalamic nucleus
- Dose-dependent effects
  - acute effects, 737
  - apomorphine, 107
  - behavioral tolerance, 737
  - body temperature, 451
  - catalepsy, 765
  - cholecystokinin, 569
  - chronic effects, 737
  - chronic treatment, 451
  - cocaine, 737
  - complex operant behavior, 737
  - dopamine receptor, 765
  - drug interactions, 451, 765
  - LY17155, 765
  - monkeys, 737
  - 8-OH-DPAT, 451
  - passive avoidance learning, 107
  - rate-decreasing effects, 569
  - schedule-controlled behavior, 569
- Drinking
  - chronic administration, 299
  - clorgyline, 299
  - desmethylinipramine, 299
  - lateral hypothalamus, 917
  - sulpiride, 917
- Drug
  - adinazolam, 73
  - N-allylnormetazocine, 493
  - alprazolam, 73, 511
  - $\alpha$ -amino-3-hydroxy-5-methyl isoxazole-4-propionate, 379
  - 2-amino-5-phosphonovaleric acid, 529
  - amphetamine, 489, 535, 641, 871
  - d-amphetamine, 45, 309, 853, 1085, 1089, 1093
  - dl-amphetamine, 899
  - (-)-anabasine, 255
  - apomorphine, 77, 107, 143, 189, 457, 463, 641, 683, 753, 889
  - arecoline, 1093
  - atropine, 625
  - baclofen, 995
  - bicuculline, 337, 995
  - bremazocine, 817
  - 4-bromo-2,5-dimethoxyphenethylamine, 597
  - buprenorphine, 195, 977
  - buspirone, 55, 723, 775, 1071
  - $\gamma$ -butyrolactone, 45
  - caffeine, 707, 809
  - cannabidiol, 675
  - cannabinol, 675
  - carbachol, 129
  - carbamazepine, 409
  - cathinone, 755, 1089
  - CGS 10746B, 1089
  - chlordiazepoxide, 209, 331, 515, 775, 1071
  - chlorpromazine, 603
  - 7-(2-chloroethyl)-theophylline, 155
  - citalopram, 613
  - clenbuterol, 417
  - clomipramine, 451
  - clonazepam, 749
  - clonidine, 77, 451, 471, 925
  - clorgyline, 299, 347, 451
  - clozapine, 603
  - cocaine, 1, 243, 589, 737, 1089
  - codeine, 115
  - corticosterone, 101
  - (dl)-cyclazocine, 163
  - (l)-cyclazocine, 163
  - cyclophosphamide, 859
  - (-)-cytisine, 255
  - desipramine, 21, 1045
  - desmethylinipramine, 137, 299
  - dexfenfluramine, 89
  - diazepam, 115, 303, 331, 479, 679, 755, 853, 945, 995
  - dihydroergocristine, 961
  - 5,6-dihydroxytryptamine, 319
  - dilezep, 155
  - diprenorphine, 977
  - DOM, 617
  - l-dopa, 77, 585
  - dopamine, 365, 641, 693
  - DPS-4, 137
  - enalapril, 823
  - estazolam, 73
  - ethanol, 55, 155, 177, 501, 769, 781, 867, 933
  - ethyl  $\beta$ -carboline-3-carboxylate, 243
  - ethylketocyclazocine, 817
  - d-fenfluramine, 715
  - fantanyl, 879
  - FG 7142, 351, 701
  - flumazenil, 945
  - fluoxetine, 77, 823, 1045

$\alpha$ -flupenthixol, 693  
GBR-13069, 1077  
gepirone, 723  
haloperidol, 55, 309, 451, 585, 589, 603, 683  
heroin, 443, 977, 983  
8-hydroxy-2-(di-n-propylamino) tetralin, 723  
3-hydroxykynurenine, 665  
l-5-hydroxytryptophan, 613  
imipramine, 1, 451, 775, 889  
isofloxythepin, 1081  
isoproterenol, 417  
ketamine, 421  
kynurenic acid, 529  
(-)-lobeline, 255  
[<sup>3</sup>H]lormetazepam, 679  
loxapine, 603  
LSD, 613, 617  
LY 171555, 55, 453  
d-lysergic acid diethylamine, 427, 433  
marijuana, 539  
MDMT, 617  
mecamylamine, 149  
medroxyprogesterone acetate, 829  
5-MeODMT, 55, 679  
meprobamate, 775  
metergoline, 451  
methadone, 357  
methaqualone, 483  
methiotepin, 451  
5-methoxy DMT, 77  
5-methoxytryptamine, 847  
methylalntrexone, 687  
methylphenidate, 879  
MK-801, 205  
molindone, 603  
morphine, 13, 123, 243, 319, 397, 569, 577, 635, 687, 693, 755, 775, 789, 853, 905, 1021, 1051, 1077  
MR 2266, 817  
nadolol, 417  
naloxone, 13, 45, 451, 543, 589, 635, 791, 905, 967, 1077  
naltrexone, 115, 163, 569, 817  
nicotine, 119, 149, 199, 217, 227, 235, 243, 249, 269, 403, 879, 1059, 1065  
(-)-nicotine, 255  
(+)-nicotine, 255  
nisoxetine, 1085  
nitrous oxide, 83  
nomifensine, 1077  
<sup>3</sup>H-norepinephrine, 391  
8-OH-DPAT, 55, 451, 613, 617  
parachlorophenylalanine, 847  
pentobarbital, 995  
pentyletetrazol, 479  
phencyclidine, 31, 205, 371, 493, 1035  
l-phenylcyclohexane, 1035  
phenobarbital, 879, 995  
phenoxybenzamine, 451  
phenylephrine, 77  
picrotoxin, 995  
pimozide, 641  
pindolol, 451  
pirenperone, 37, 55, 613, 617  
pirenzepine, 519  
pizotifen, 55  
pizotyline, 613, 617  
propranolol, 451  
(-)-propranolol, 55  
quinpirole, 189, 457, 525  
quinuclidinyl benzilate, 31

quipazine, 37, 55  
ritanserlin, 451, 853  
RO 4-4602, 613  
RO 5-4864, 749  
RO 15-1788, 331  
RO 15-3505, 701  
RO 15-4513, 183, 501, 701, 867, 1045  
RU-24969, 617  
salbutamol, 77  
SCH 23390, 463, 683, 765  
scopolamine, 119, 205, 295, 625, 949, 1093  
semicarbazide, 337  
SKF 38393, 55, 189, 457, 463  
SMS 201-995, 295  
strychnine, 995  
sulpiride, 917  
(-)-sulpiride, 765  
tamoxifen, 829  
TFMPP, 55, 613, 617  
theophylline, 155  
thioridazine, 641  
THIP, 995  
triazolam, 73  
U50488H, 755  
YM 09151-2, 463  
zolantidine, 791  
Drug-admixed food method, 483  
methaqualone  
physical dependence  
sex differences  
Drug comparisons  
anxiolytics, 1071  
buprenorphine, 977  
buspirone, 723, 1071  
central benzodiazepine agonist, 749  
chlordiazepoxide, 1071  
citalopram, 613  
clonazepam, 749  
clozapine, 603  
defensive burying, 1071  
differential tolerance, 977  
discriminative stimulus, 613  
dopamine-mediated behavior, 463  
fixed-consecutive-number responding, 603  
food intake, 977  
gepirone, 723  
heroin, 977  
8-hydroxy-2-(di-n-propyl-amino)tetralin, 723  
l-5-hydroxytryptophan, 613  
monkeys, 977  
NaCl intake, 749  
peripheral benzodiazepine agonist, 749  
pigeons, 723  
RO 4-46202, 613  
RO 5-4864, 749  
shock-probe test, 1071  
unpunished responding, 723  
Drug discrimination  
d-amphetamine, 1085, 1089  
 $\beta$ -carboline, 351  
CGS 10746B, 1089  
drug interactions, 55  
dopamine receptors, 55  
ethanol, 55  
FG 7142, 351  
footshock, 351  
nisoxetine, 1085  
novel environment, 351  
serotonin receptors, 55  
Drug interactions

amphetamine, 641  
d-amphetamine, 45, 853  
amphetamine anorexia, 641  
anxiety, 701  
behavioral/electrocorticographic comparisons, 479  
behavioral microanalysis, 641  
benzodiazepine receptors, 701  
body temperature, 451, 675  
 $\gamma$ -butyrolactone, 45  
cannabidiol, 675  
cannabinol, 675  
catalepsy, 765  
catecholamines, 589  
chemoconvulsants, 995  
chronic treatment, 451  
conditioned place preference, 853  
diazepam, 479, 853  
discriminative stimulus, 617  
dopamine, 641  
dopamine receptor, 55, 765  
dose-dependent effects, 451, 765  
drug discrimination, 55  
endogenous opioids, 589  
ethanol, 55, 501, 701, 867  
GABAergic drugs, 995  
GABAergic system, 501  
lever pressing, 45  
light/dark choice paradigm, 867  
locus coeruleus, 13  
locus coeruleus stimulation, 13  
lordosis, 37  
LSD, 617  
LY 17155, 765  
alpha-melanocyte stimulating hormone, 37  
molecular interactions, 501  
monkeys, 13  
morphine, 13, 853  
morphine withdrawal, 13  
naloxone, 13, 45  
8-OH-DPAT, 451  
open-field activity, 675  
pentobarbital, 995  
pentyletetrazol, 479  
phencyclidine, 1035  
phenobarbital, 995  
l-phenylcyclohexane, 1035  
plus-maze test, 701  
rat pups, 479  
ritanserlin, 853  
RO 15-4513, 501, 867  
self-stimulation reward, 589  
serotonin, 37  
serotonergic agonists, 617  
serotonergic antagonists, 617  
serotonin receptors, 55  
staircase test, 867  
ventral tegmental area, 589  
Drug self-administration, 227  
human studies  
intravenous administration  
nicotine  
reinforcing effects  
Drugs of abuse, 597  
4-bromo-2,5-dimethoxyphenethylamine  
Eating  
chronic administration, 299  
clorgyline, 299  
desmethylimipramine, 299  
lateral hypothalamus, 917

- sulpiride, 917
- EEDQ, 457
  - D<sub>1</sub>/D<sub>2</sub> agonists
  - dopamine
  - rotational behavior
  - selective protection
- EEG power spectra, 489
  - amphetamine
  - motor activity
- Eight-arm radial maze, 119
  - nicotine
  - scopolamine
- Electrical stimulation, 397
  - approach response
  - differential effects
  - escape response
  - intracerebral microinjection
  - lateral hypothalamus
  - morphine
- Electroencephalogram, 149
  - human studies, males
  - mecamylamine
  - nicotine
  - nicotine gum
- Embryos, chicken, 357
  - continuous infusion
  - methadone
  - opioid dependence
  - osmotic mini-pump
- Endogenous opioids, 589
  - catecholamines
  - drug interactions
  - self-stimulation reward
  - ventral tegmental area
- $\beta$ -Endorphin levels, 933
  - ethanol
  - ethanol withdrawal
  - pituitary
- Environment-specific conditioning, 525
  - dopamine receptor
  - quinpirole
- Escape, 957
  - frogs
  - skin mucus
  - tardive dyskinesia
- Escape response, 397
  - approach response
  - differential effects
  - electrical stimulation
  - intracerebral injection
  - lateral hypothalamus
  - morphine
- Estrous cycle, 563
  - monoamines
  - postpartum period
  - pregnancy
- Ethanol
  - acute administration, 769
  - adenosine, 155
  - anxiety, 701
  - autoradiography, 781
  - benzodiazepine receptors, 701
  - brain regional uptake, 781
  - cerebellum, 155
  - chlordiazepoxide, 385
  - chronic intake, 385
  - cross-tolerance, 385
  - 2-deoxyglucose, 781
  - dopamine receptors, 55
  - drug discrimination, 55
  - drug interactions, 55, 501, 701, 867
  - $\beta$ -endorphin levels, 933
  - ethanol tolerance, 385
  - ethanol withdrawal, 933
  - GABAergic system, 501
  - hippocampus, 177
  - light/dark choice paradigm, 867
  - MHPG-SO<sub>4</sub>, 769
  - molecular interactions, 501
  - motor incoordination, 155
  - noradrenaline metabolism, 769
  - pituitary, 933
  - plus-maze test, 701
  - rhythmic slow activity, 177
  - RO 15-4513, 501, 867
  - serotonin receptors, 55
  - spontaneous motor activity inhibition, 155
  - staircase test, 867
  - strain differences, 177, 769, 781
- Ethanol antagonism, 183
  - differential sensitivity
  - RO 15-4513
  - strain differences
- Ethanol intake, 1045
  - desipramine
  - fluoxetine
  - food intake
  - RO 15-4513
  - strain differences
  - water intake
- Ethanol tolerance, 385
  - chlordiazepoxide
  - chronic intake
  - cross-tolerance
  - ethanol
- Ethanol withdrawal, 933
  - $\beta$ -endorphin levels
  - ethanol
  - pituitary
- Ethylketocyclazocine, 817
  - analgesia
  - bremazocine
  - neonatal administration
- Excitatory amino acid antagonists, 529
  - ingestive behaviors
  - median raphe nucleus
- Feeding behavior, 925
  - clonidine
- d-Fenfluramine, 715
  - serotonin metabolism, brain
  - uptake inhibition
- FG 7142, 351
  - $\beta$ -carbolines
  - drug discrimination
  - footshock
  - novel environment
- Fixed-consecutive-number responding, 603
  - clozapine
  - drug comparisons
- Flash evoked potentials, 421
  - ketamine
- Flight behavior, 337
  - bicuculline
  - microinjection
  - rats, detelencephalated
  - semicarbazide
- Flumazenil, 945
  - diazepam
  - dogs
  - oral absorption
- Fluoxetine, 1045
  - desipramine
  - ethanol intake
- food intake
  - RO 15-4513
  - strain differences
  - water intake
- Food intake
  - buprenorphine, 977
  - desipramine, 1045
  - differential tolerance, 977
  - diprenorphine, 977
  - drug comparisons, 977
  - ethanol intake, 1045
  - fluoxetine, 1045
  - heroin, 977
  - intravenous self-administration, 1051
  - lesions, 6-hydroxydopamine, 1051
  - monkeys, 977
  - morphine, 1051
  - nucleus accumbens, 1051
  - RO 15-4513
  - strain differences, 1045
  - water intake, 1045
- Food restriction, 649
  - ad lib feeding
  - body weight restriction
  - dorsomedial hypothalamic nucleus
  - lesions, dorsomedial hypothalamic nucleus
- Footshock, 351
  - $\beta$ -carbolines
  - drug discrimination
  - FG 7142
  - novel environment
- Four-drug discrimination, 879
  - identical levers
  - response manipulation
- Freezing behavior, 801
  - corticotropin-releasing hormone
  - intracerebroventricular administration
  - pain sensitivity
- Frogs, 957
  - escape
  - skin mucus
  - tardive dyskinesia
- Frontal cortex, 129
  - anatomical analysis
  - carbachol
  - motor seizures
- Functional neuroanatomy, 983
  - auditory stimulus
  - heroin
- GABA agonists, 657
  - lateral hypothalamus
  - reward effect
  - self-stimulation
- GABAergic drugs, 995
  - chemoconvulsants
  - drug interactions
  - pentobarbital
  - phenobarbital
- GABAergic system, 501
  - drug interactions
  - ethanol
  - molecular interactions
  - RO 15-4513
- GABA-gated chloride channels, 911
  - asymmetrical activation
  - cerebral cortex
- Genetic analysis, 143
  - apomorphine
  - climbing behavior
  - locomotor behavior
- Genetic breeding, 343

- angiotensins
- blood pressure responsiveness
- intracarotid infusion
- Genetic differences, 1059
  - nicotine
  - plasma corticosterone levels
- Genetic influence, 269
  - acute response
  - nicotine
  - nicotine tolerance
- Gepirone, 723
  - bupirone
  - drug comparisons
  - 8-hydroxy-2-(di-n-propyl-amino)tetralin
  - pigeons
  - unpunished responding
- Haloperidol
  - apomorphine, 683
  - body temperature, 683
  - chronic administration, 585
  - l-dopa, 585
  - rebound enhancement, 585
  - SCH 23390, 683
  - self-stimulation, 585
- Heart, 1015
  - kidney
  - peripheral benzodiazepine receptors
  - [<sup>3</sup>H] RO 5-4864 binding
  - stress
- Heroin
  - antagonist treatment, 443
  - auditory stimulus, 983
  - buprenorphine, 977
  - differential tolerance, 977
  - diprenorphine, 977
  - drug comparisons, 977
  - food intake, 977
  - functional neuroanatomy, 983
  - intravenous self-administration, 443
  - monkeys, 977
  - nucleus accumbens, 443
  - periaqueductal grey, 443
- High performance liquid chromatography, 795
  - biogenic amines
  - discrete brain regions
- Hippocampus
  - conditioned place preference, 787
  - ethanol, 177
  - morphine, 787
  - rhythmic slow activity, 177
  - strain differences, 177
- Hormone
  - alphaxalone, 729
  - progesterone, 729
- H<sub>2</sub>-receptor, 791
  - adrenalectomy
  - analgesia, stress-induced
  - hypophysectomy
- Human studies
  - drug self-administration, 227
  - intravenous administration, 227
  - marijuana smoke, 895
  - nicotine, 217, 227
  - nitrous oxide, 83
  - pharmacologic determinants, 221
  - pharmacological effects, 217
  - reinforcing effects, 227
  - salivary cotinine, 895
  - serum cotinine, 895
  - state-dependent memory, 83
  - tobacco dependence, 217
  - tobacco self-administration, 221
  - tobacco smoke, 895
- Human studies, males
  - electroencephalogram, 149
  - marijuana, 539
  - mecamylamine, 149
  - metabolic data, 249
  - naloxone, 967
  - nicotine, 149, 249
  - nicotine gum, 149
  - nicotine metabolism, 249
  - prolactin response, 967
  - psychopharmacology, 967
  - small groups, 539
  - social behavior, 539
- Hunger-mimetic model, 515
  - benzodiazepines
  - chlordiazepoxide
  - hyperphagia
- 8-Hydroxy-2-(di-n-propyl-amino)tetralin, 723
  - bupirone
  - drug comparisons
  - gepirone
  - pigeons
  - unpunished responding
- 3-Hydroxykynurenine, 665
  - benzodiazepine receptor binding
  - affinity
  - neonatal deficiency
  - seizures
  - vitamin B-6
- 5-Hydroxytryptamine receptors, 347
  - circadian studies
  - clorgyline
- l-5-Hydroxytryptophan, 613
  - citalopram
  - discriminative stimulus
  - drug comparisons
  - RO 4-46202
- Hyperactivity, 577
  - dopamine
  - median raphe nucleus
  - morphine
- Hyperlocomotion, 309
  - amphetamine
  - cholecystokinin-octapeptide
  - intra-accumbens injections
  - intracerebroventricular injection
  - route of administration
  - stereotypy
- Hypermotility, 379
  - α-amino-3-hydroxy-5-methylisoxazole-4-propionate
  - nucleus accumbens
  - quisqualic acid receptors
- Hyperphagia, 515
  - benzodiazepines
  - chlordiazepoxide
  - hunger-mimetic model
- Hypophysectomy, 791
  - adrenalectomy
  - analgesia, stress-induced
  - H<sub>2</sub>-receptor
- Hypotension, 65
  - antinociception
  - bradycardia
  - intrathecal antagonists
  - intravenous administration
  - [D-Ala<sup>2</sup>]-methionine enkephalinamide
- Hypothalamus, 169
  - chronic stress
  - [<sup>3</sup>H]cyclohexyladenosine
  - receptor ligand binding
- Hypothermia, 941
  - brain, rat
  - thyrotropin-releasing hormone
- Identical levers, 879
  - four-drug discrimination
  - response manipulandum
- Imipramine
  - cocaine, 1
  - interactive effects, 1
  - long-term treatment, 889
  - place preference, apomorphine-induced, 889
  - place preference, food-induced
  - self-stimulation, 1
  - short-term treatment, 889
  - train-duration thresholds, 1
- Immobility response, 625
  - atropine
  - chickens
  - scopolamine
  - strain differences
- Inescapable stress, 21
  - daily running activity
  - desipramine
  - long-term effects
- Ingestive behaviors, 529
  - excitatory amino acid antagonists
  - median raphe nucleus
- Interactive effects, 1
  - cocaine
  - imipramine
  - self-stimulation
  - train-duration thresholds
- Intestinal inhibition, 319
  - analgesia
  - morphine
  - supraspinal cerebral areas
- Intra-accumbens injection, 309
  - amphetamine
  - cholecystokinin-octapeptide
  - hyperlocomotion
  - intracerebroventricular injection
  - route of administration
  - stereotypy
- Intracarotid infusion, 343
  - angiotensins
  - blood pressure responsiveness
  - genetic breeding
- Intracerebral microinjection, 397
  - approach response
  - differential effects
  - electrical stimulation
  - escape response
  - lateral hypothalamus
  - morphine
- Intracerebroventricular administration, 801
  - corticotropin-releasing hormone
  - freezing behavior
  - pain sensitivity
- Intracerebroventricular injection, 309
  - amphetamine
  - cholecystokinin-octapeptide
  - hyperlocomotion
  - intra-accumbens injection
  - route of administration
  - stereotypy



- Intrathecal antagonists, 65
  - antinociception
  - bradycardia
  - hypotension
  - intravenous administration
  - [D-Ala<sup>2</sup>]-methionine enkephalinamide
- Intravenous administration
  - antinociception, 65
  - bradycardia, 65
  - drug self-administration, 227
  - human studies, 227
  - hypotension, 65
  - intrathecal antagonists, 65
  - [D-Ala<sup>2</sup>]-methionine enkephalinamide
  - monkeys, 243
  - reinforcing effects, 227
- Intravenous self-administration
  - antagonist treatment, 443
  - food intake, 1051
  - heroin, 443
  - lesions, 6-hydroxydopamine, 1051
  - morphine, 1051
  - nucleus accumbens, 443, 1051
  - periaqueductal grey, 443
- Inverse benzodiazepine agonists, 5
  - in vitro
  - in vivo
  - neuropharmacology
  - rabbits
- Investigatory behavior, 417
  - clenbuterol
  - locomotor activity
  - peripheral mediation
- In vitro, 5
  - inverse benzodiazepine agonists
  - in vivo
  - neuropharmacology
  - rabbits
- In vitro autoradiography, 679
  - benzodiazepine binding sites
  - substantia innominata
- In vivo
  - inverse benzodiazepine agonists, 5
  - in vitro, 5
  - neuropharmacology, 5
  - parametric studies, 31
  - phencyclidine, 31
  - quinuclidinyl benzilate, 31
  - rabbits, 5
- Ionizing radiation, 1007
  - schedule-controlled performance
  - sublethal doses
- Ischymetric mechanisms, 89
  - anorexia
  - dexfenfluramine
  - lipostatic mechanisms
  - metabolic chamber
- Isofloxythepin, 1081
  - isofloxythepin enantiomers
  - postdecapitation convulsions
  - prolactin secretion
- Isofloxythepin enantiomers, 1081
  - isofloxythepin
  - postdecapitation convulsions
  - prolactin secretion
- Jumping, naloxone-induced, 905
  - analgesia, morphine-induced
  - morphine
  - naloxone
  - restraint
- Ketamine, 421
  - flash evoked potentials
- Kidney, 1015
  - heart
  - peripheral benzodiazepine receptors
  - [<sup>3</sup>H] RO 5-4864 binding
  - stress
- Latent inhibition disruption, 871
  - acute administration
  - amphetamine
- Lateral hypothalamus
  - approach response, 397
  - differential effects, 397
  - dopamine, 365
  - drinking, 917
  - eating, 917
  - electrical stimulation, 397
  - escape response, 397
  - GABA agonists, 657
  - intracerebral microinjection, 397
  - morphine, 397
  - neonatal depletions, 365
  - rats, adult, 365
  - reward effect, 657
  - self-stimulation, 657
  - stimulation reward, 365
  - sulpiride, 917
- Learning, 835
  - dorsal noradrenergic bundle
  - lesions, 6-hydroxydopamine
  - memory
- Learning and memory, 961
  - dihydroergocristine
  - rats, aged males
- Lesions, dorsomedial hypothalamic nucleus, 649
  - ad lib feeding
  - body weight restriction
  - dorsomedial hypothalamic nucleus
  - food restriction
- Lesions, 6-hydroxydopamine
  - aversive effects, 693
  - dopamine innervation, 693
  - dorsal noradrenergic bundle, 835
  - food intake, 1051
  - intravenous self-administration, 1051
  - learning, 835
  - memory, 835
  - morphine, 1051
  - nucleus accumbens, 1051
  - opiates, 693
  - visceral cortex, 693
- Lever pressing, 45
  - d-amphetamine
  - γ-butyrolactone
  - drug interactions
  - naloxone
- Light/dark choice paradigm, 867
  - drug interactions
  - ethanol
  - RO 15-4513
  - staircase test
- Lipostatic mechanisms, 89
  - anorexia
  - dexfenfluramine
  - ischymetric mechanisms
  - metabolic chamber
- Locomotor behavior
  - aggressive behavior, 729
  - alphaxalone, 729
  - amphetamine, 535
  - apomorphine, 143
  - circadian rhythm, 535
  - clenbuterol, 417
  - climbing behavior, 143
  - comparative effects, 729
  - continuous administration, 535
  - genetic analysis, 143
  - investigatory behavior, 417
  - peripheral mediation, 417
  - progesterone, 729
  - reproductive behavior, 729
  - stereotypy, 535
- Locus coeruleus, 13
  - drug interactions
  - locus coeruleus stimulation
  - monkeys
  - morphine
  - morphine withdrawal
  - naloxone
- Locus coeruleus stimulation, 13
  - drug interactions
  - locus coeruleus
  - monkeys
  - morphine
  - morphine withdrawal
  - naloxone
- Long-term effects, 21
  - daily running activity
  - desipramine
  - inescapable stress
- Long-term treatment, 889
  - imipramine
  - place preference, apomorphine-induced
  - place preference, food-induced
  - short-term treatment
- Lordosis, 37
  - drug interactions
  - alpha-melanocyte stimulating hormone
  - serotonin
- Low-dose administration, 511
  - alprazolam
  - motor activity
- LSD, 617
  - discriminative stimulus
  - drug interactions
  - serotonergic agonists
  - serotonergic antagonists
- LY17155, 765
  - catalepsy
  - dopamine receptor
  - dose-dependent effects
  - drug interactions
- d-Lysergic acid diethylamide
  - classical conditioning, 433
  - classical trace conditioning, 427
  - CS-UCS interval, 433
  - reflex facilitation, 433
- Marijuana, 539
  - human studies, males
  - small groups
  - social behavior
- Marijuana smoke, 895
  - human studies
  - salivary cotinine
  - serum cotinine
  - tobacco smoke
- Maternal stress, 669
  - 5-MeODMT
  - open-field activity

- postnatal factors
  - prenatal factors
- Mecamylamine, 149
  - electroencephalogram
  - human studies, males
  - nicotine
  - nicotine gum
- Median raphe nucleus
  - dopamine, 577
  - excitatory amino acid antagonists, 529
  - hyperactivity, 577
  - ingestive behaviors, 529
  - morphine, 577
- Medroxyprogesterone acetate, 829
  - aggressive behavior
  - mice, male
  - tamoxifen
- alpha-Melanocyte stimulating hormone, 37
  - drug interactions
  - lordosis
  - serotonin
- Memory, 835
  - dorsal noradrenergic bundle
  - learning
  - lesions, 6-hydroxydopamine
- Memory retrieval, 77
  - active avoidance
  - aminergic neurotransmitter systems
  - pharmacological stimulation
- 5-MeODMT, 669
  - maternal stress
  - open-field activity
  - postnatal factors
  - prenatal factors
- Metabolic chamber, 89
  - anorexia
  - dexfenfluramine
  - isometric mechanisms
  - lipostatic mechanisms
- Metabolic data, 249
  - human studies, males
  - nicotine
  - nicotine metabolism
- Methadone, 357
  - continuous infusion
  - embryos, chicken
  - opioid dependence
  - osmotic mini-pumps
- Methaqualone, 483
  - drug-admixed food method
  - physical dependence
  - sex differences
- [D-Ala<sup>2</sup>]-Methionine enkephalinamide, 65
  - antinociception
  - bradycardia
  - hypotension
  - intrathecal antagonists
  - intravenous administration
- Method
  - autoradiography, 325, 781
  - drug-admixed food method, 483
  - gas chromatography-mass spectrometry, 249
  - high performance liquid chromatography, 795
  - Montgomery's conflict test, 471
  - Vogel's conflict test, 471
- 5-Methoxytryptamine, 847
  - behavioral effects
  - parachlorophenylalanine
  - prenatal exposure
  - serotonin uptake
- Methylnaltrexone, 687
  - conditioned taste aversion
  - morphine
  - opiate aversive effects
  - preexposure effects
- Methylxanthines, 707
  - adenosine receptors
  - autoradiography
  - strain differences
- MHPG-SO<sub>4</sub>, 769
  - acute administration
  - ethanol
  - noradrenaline metabolism
  - strain differences
- Mice, female, 859
  - conditioned stimulus
  - cyclophosphamide
  - T-cell antibody responses
  - unconditioned stimulus
- Mice, male, 829
  - aggressive behavior
  - medroxyprogesterone acetate
  - tamoxifen
- Microinjection, 337
  - bicuculline
  - flight behavior
  - rats, detelencephalated
  - semicarbazide
- Midbrain periaqueductal gray, 409
  - aggression
  - carbamazepine
  - cats
- MK-801, 205
  - amnesia
- Molecular interactions, 501
  - drug interactions
  - ethanol
  - GABAergic system
  - RO 15-4513
- Monkeys
  - acute effects, 737
  - behavioral tolerance, 737
  - buprenorphine, 977
  - chronic effects, 737
  - cocaine, 737
  - complex operant behavior, 737
  - differential tolerance, 977
  - diprenorphine, 977
  - dose-dependent effects, 737
  - drug comparisons, 977
  - drug interactions, 13
  - food intake, 977
  - heroin, 977
  - intravenous administration, 243
  - locus coeruleus, 13
  - locus coeruleus stimulation, 13
  - morphine, 13
  - morphine withdrawal, 13
  - naloxone, 13
  - nicotine, 243
- Monoamines, 563
  - estrous cycle
  - postpartum period
  - pregnancy
- Morphine
  - d-amphetamine, 853
  - analgesia, 123, 319
  - analgesia, morphine-induced, 905
  - approach response, 397
  - circling behavior, 1077
  - conditioned place preference, 787, 853
  - conditioned taste aversion, 687
  - crabs, 635
  - defensive response, 635
  - diazepam, 853
  - differential effects, 397
  - dopamine, 577
  - dopaminergic uptake blocker, 1077
  - drug interactions, 13, 853
  - electrical stimulation, 397
  - escape response, 397
  - food intake, 1051
  - hippocampus, 787
  - hyperactivity, 77
  - intestinal inhibition, 319
  - intracerebral microinjection, 397
  - intravenous self-administration, 1051
  - jumping, naloxone-induced
  - lateral hypothalamus, 397
  - lesions, 6-hydroxydopamine, 1051
  - locus coeruleus, 13
  - locus coeruleus stimulation, 13
  - median raphe nucleus, 577
  - methylnaltrexone, 687
  - monkeys, 13
  - morphine withdrawal, 13
  - naloxone, 13, 635, 905
  - nucleus accumbens, 1051
  - opiate aversive effects, 687
  - preexposure effects, 687
  - prenatal stress, 123
  - restraint, 905
  - ritanserin, 853
  - sex differences, 123
  - supraspinal cerebral areas, 319
- Morphine withdrawal, 13
  - drug interactions
  - locus coeruleus
  - locus coeruleus stimulation
  - monkeys
  - morphine
  - naloxone
- Morris Water Maze, 519
  - pirenzepine
  - spatial learning
- Motor activity
  - alprazolam, 511
  - amphetamine, 489
  - EEG power spectra, 489
  - low-dose administration, 511
- Motor development, 199
  - activity meter
  - nicotine
  - prenatal changes
- Motor incoordination, 155
  - adenosine
  - cerebellum
  - ethanol
  - spontaneous motor activity inhibition
- Motor seizures, 129
  - anatomical analysis
  - carbachol
  - frontal cortex
- NaCl intake, 749
  - central benzodiazepine agonist
  - clonazepam
  - drug comparisons
  - peripheral benzodiazepine agonist
  - RO 5-4864
- Naloxone
  - d-amphetamine, 45
  - analgesia, morphine-induced, 905
  - γ-butyrolactone, 45

- cats, 543
- crabs, 635
- defensive response, 635
- drug interactions, 13, 45
- human studies, males, 967
- jumping, naloxone-induced, 905
- lever pressing, 45
- locus coeruleus, 13
- locus coeruleus stimulation, 13
- monkeys, 13
- morphine, 13, 635, 905
- morphine withdrawal, 13
- penile erection, 543
- prolactin response, 967
- psychopharmacology, 967
- restraint, 905
- Naltrexone, 163
  - cyclazocine
  - dissociation
  - nonopioid effects
  - opioid effects
- Neonatal administration, 817
  - analgesia
  - bremazocine
  - ethylketocyclazocine
- Neonatal deficiency, 665
  - benzodiazepine receptor binding
    - affinity
    - 3-hydroxykynurenine
    - seizures
    - vitamin B-6
- Neonatal depletions, 365
  - dopamine
  - lateral hypothalamus
  - rats, adult
  - stimulation reward
- Neuropharmacology, 5
  - inverse benzodiazepine agonists, 5
  - in vitro
  - in vivo
  - rabbits
- Nicotine
  - activity meter, 199
  - acute pretreatment, 1065
  - acute response, 269
  - carbamate esters, 403
  - central nicotinic receptors, 235
  - conditioned taste aversion, 235
  - discriminative stimulus, 235
  - drug self-administration, 227
  - eight-arm radial maze
  - electroencephalogram, 149
  - genetic differences, 1059
  - genetic influence, 269
  - human studies, 217, 227
  - human studies, males, 149, 249
  - intravenous administrations, 227, 243
  - mecamylamine, 149
  - metabolic data, 249
  - monkeys, 243
  - motor development, 199
  - nicotine agonists, 403
  - nicotine antagonists, 403
  - nicotine gum, 149
  - nicotine metabolism, 249
  - nicotine tolerance, 269
  - pharmacological effects, 217
  - plasma corticosterone levels, 1059, 1065
  - prenatal changes, 199
  - reinforcing effects, 227
  - scopolamine, 119
  - strain differences, 1065
  - structure-activity studies, 403
  - tobacco dependence, 217
- Nicotine agonists, 403
  - carbamate esters
  - nicotine
  - nicotine antagonists
  - structure-activity studies
- Nicotine antagonists, 403
  - carbamate esters
  - nicotine
  - nicotine agonists
  - structure-activity studies
- Nicotine gum
  - electroencephalogram, 149
  - human studies, males, 149
  - mecamylamine, 149
  - nicotine, 149
  - pharmacological treatment, 279
  - tobacco dependence, 279
- Nicotine metabolism, 249
  - human studies, males
  - metabolic data
  - nicotine
- Nicotine tolerance, 269
  - acute response
  - genetic influence
  - nicotine
- Nicotinic ligands, 255
  - binding characteristics
  - pharmacologic analysis
- Nisoxetine, 1085
  - d-amphetamine
  - drug discrimination
- Nitrous oxide, 83
  - human studies
  - state-dependent memory
- Nociception, 209
  - chlordiazepoxide
  - contextual fear
  - shock controllability
- Nonopioid effects, 163
  - cyclazocine
  - dissociation
  - naltrexone
  - opioid effects
- Noradrenaline metabolism, 769
  - acute administration
  - ethanol
  - MHPG-SO<sub>4</sub>
  - strain differences
- Norepinephrine, 137
  - cerebral depletion
  - conditioned avoidance responding
- <sup>3</sup>H-Norepinephrine uptake, 391
  - (1-24)adrenocorticotrophic hormone
  - atria, rat
- Novel environment, 351
  - $\beta$ -carbolines
  - drug discrimination
  - FG 7142
  - footshock
- Nucleus accumbens
  - $\alpha$ -amino-3-hydroxy-5-methylisoxazole-4-propionate, 379
  - antagonist treatment, 443
  - food intake, 1051
  - heroin, 443
  - hypermotility, 379
  - intravenous self-administration, 443, 1051
  - lesions, 5-hydroxydopamine, 1051
  - morphine, 1051
  - periaqueductal grey, 443
  - quisqualic acid receptors, 379
- 8-OH-DPAT, 451
  - body temperature
  - chronic treatment
  - dose-dependent effects
  - drug interactions
- Open-field activity
  - body temperature, 675
  - cannabidiol, 675
  - cannabinol, 675
  - drug interactions, 675
  - maternal stress, 669
  - 5-MeODMT, 669
  - postnatal factors, 669
  - prenatal factors, 669
- Opiate aversive effects, 687
  - conditioned taste aversion
  - methylnaltrexone
  - morphine
    - preexposure effects
- Opiate mechanisms, 755
  - amphetamine
  - anorectic effects
  - tolerance development
  - U50488H
- Opiates, 693
  - aversive effects
  - dopamine innervation
  - lesions, 6-OHDA
  - visceral cortex
- Opioid dependence, 357
  - continuous infusion
  - embryos, chicken
  - methadone
  - osmotic minipumps
- Opioid effects, 163
  - cyclazocine
  - dissociation
  - naltrexone
  - nonopioid effects
- Opioids, 1021
  - rat, male
  - sexual behavior
- Oral absorption, 945
  - diazepam
  - dogs
  - flumazenil
- Oral self-administration, 493
  - N-allylnormetazocine
  - phencyclidine
  - rhesus monkeys
  - withdrawal
- Osmotic mini-pumps, 357
  - continuous infusion
  - embryos, chicken
  - methadone
  - opioid dependence
- Pain sensitivity, 801
  - corticotropin-releasing hormone
  - freezing behavior
  - intracerebroventricular administration
- Parachlorophenylalanine, 847
  - behavioral effects
  - 5-methoxytryptamine
  - prenatal exposure
  - serotonin uptake
- Paradoxical sleep suppression, 295
  - scopolamine

SMS 201-995  
Parametric studies, 31  
  in vivo  
  phencyclidine  
  quinuclidinyl benzilate  
Passive avoidance learning, 107  
  apomorphine  
  dose-dependent effects  
Penile erection, 543  
  cats  
  naloxone  
Pentobarbital, 995  
  chemoconvulsants  
  drug interactions  
  GABAergic drugs  
  phenobarbital  
Pentylentetrazol, 479  
  behavioral/electrocorticographic  
  comparisons  
  diazepam  
  drug interactions  
  rat pups  
Peptides  
  (1-24)adrenocorticotrophic hormone,  
  391  
  D-Ala<sup>2</sup>-Met<sup>5</sup>-enkephalinamide, 1021  
  [D-Ala<sup>2</sup>]-methionine enkephalin-  
  amide, 65  
  angiotensin II, 343  
  angiotensin III, 343  
  caerulein, 957  
  cholecystokinin, 569, 957  
  cholecystokinin-octapeptide, 309  
  corticotropin-releasing hormone, 801  
  alpha-melanocyte stimulating  
  hormone, 37  
  serotonin, 37, 957  
  thyrotropin-releasing hormone, 73,  
  941, 957  
  xenopsin, 957  
Periaqueductal grey, 443  
  antagonist treatment  
  heroin  
  intravenous self-administration  
  nucleus accumbens  
Peripheral benzodiazepine agonist, 749  
  central benzodiazepine agonist  
  clonazepam  
  drug comparisons  
  NaCl intake  
  RO 5-4864  
Peripheral benzodiazepine receptors, 1051  
  heart  
  kidney  
  [<sup>3</sup>H] RO 5-4864 binding  
  stress  
Pentobarbital, 995  
  chemoconvulsants  
  drug interactions  
  GABAergic drugs  
  phenobarbital  
Peripheral mediation, 417  
  clenbuterol  
  investigatory behavior  
  locomotor activity  
Pharmacologic analysis, 255  
  binding characteristics  
  nicotinic ligands  
Pharmacologic determinants, 221  
  human studies  
  tobacco self-administration  
Pharmacological stimulation  
  active avoidance, 77  
  aminergic neurotransmitter systems,  
  77  
  human studies, 217  
  memory retrieval, 77  
  nicotine, 217  
  nicotine gum, 279  
  tobacco dependence, 217, 279  
Phencyclidine  
  N-allylnormetazocine, 493  
  biodeposition, 371  
  charcoal, 371  
  drug interactions, 1035  
  in vivo, 31  
  oral self-administration, 493  
  parametric studies, 31  
  l-phenylcyclohexane, 1035  
  quinuclidinyl benzilate, 31  
  rhesus monkeys, 493  
  withdrawal, 493  
Phenobarbital, 995  
  chemoconvulsants  
  drug interactions  
  GABAergic drugs  
  pentobarbital  
l-Phenylcyclohexane, 1035  
  drug interactions  
  phencyclidine  
Physical dependence, 483  
  drug-admixed food method  
  methaqualone  
  sex differences  
Pigeons, 723  
  buspirone  
  drug comparisons  
  gepirone  
  8-hydroxy-2-(di-n-propyl-  
  amino)tetralin  
  unpunished responding  
Pirenzepine, 519  
  Morris Water Maze  
  spatial learning  
Pituitary, 933  
  β-endorphin levels  
  ethanol  
  ethanol withdrawal  
Place preference, apomorphine-induced,  
889  
  imipramine  
  long-term treatment  
  place preference, food-induced  
  short-term treatment  
Place preference, food-induced, 889  
  imipramine  
  long-term treatment  
  place preference, apomorphine-  
  induced  
  short-term treatment  
Plasma corticosterone levels  
  acute pretreatment, 1065  
  genetic differences, 1059  
  nicotine, 1059, 1065  
  strain differences, 1065  
Plus maze test, 701  
  anxiety  
  benzodiazepine receptors  
  drug interactions  
  ethanol  
Postdecapitation convulsions  
  benzodiazepines, 1001  
  isofloxythepin, 1081  
  isofloxythepin enantiomers, 1081  
  prolactin secretion, 1081  
  tonic component, 1001  
Postnatal factors, 669  
  maternal stress  
  5-MeODMT  
  open-field activity  
  prenatal factors  
Postpartum period, 563  
  estrous cycle  
  monoamines  
  pregnancy  
Preexposure effects, 687  
  conditioned taste aversion  
  methylnaltrexone  
  morphine  
  opiate aversive effects  
Pregnancy, 563  
  estrous cycle  
  monoamines  
  postpartum period  
Prenatal changes, 199  
  activity meter  
  motor development  
  nicotine  
Prenatal exposure, 847  
  behavioral effects  
  5-methoxytryptamine  
  parachlorophenylalanine  
  serotonin uptake  
Prenatal factors, 669  
  maternal stress  
  5-MeODMT  
  open-field activity  
  postnatal factors  
Prenatal stress, 123  
  analgesia  
  morphine  
  sex differences  
Proconvulsant effects, 331  
  anxiogenic effects  
  benzodiazepine receptors  
  brain, rat  
  N-butyl β carboline-3-carboxylate  
Progesterone, 729  
  aggressive behavior  
  alphaxalone  
  comparative effects  
  locomotor behavior  
  reproductive behavior  
Prolactin response, 967  
  human studies, males  
  naloxone  
  psychopharmacology  
Prolactin secretion, 1081  
  isofloxythepin  
  isofloxythepin enantiomers  
  postdecapitation convulsions  
Psychopharmacology, 967  
  human studies, males  
  naloxone  
  prolactin response  
Punished responding, 753  
  apomorphine  
  unpunished responding  
Quinpirole, 525  
  dopamine receptor  
  environment-specific conditioning  
Quinuclidinyl benzilate, 31  
  in vivo  
  parametric studies  
  phencyclidine

- Quisqualic acid receptors, 379
  - $\alpha$ -amino-3-hydroxy-5-methylisoxazole-4-propionate
  - hypermotility
  - nucleus accumbens
- Rabbits, 5
  - inverse benzodiazepine agonists
  - in vitro
  - in vivo
  - neuropharmacology
- Rat, adult, 365
  - dopamine
  - lateral hypothalamus
  - neonatal depletions
  - stimulation reward
- Rat, aged males, 961
  - dihydroergocristine
  - learning and memory
- Rat, detelencephalated, 337
  - bicuculline
  - flight behavior
  - microinjection
  - semicarbazide
- Rat, male, 1021
  - opioids
  - sexual behavior
- Rat pups, 479
  - behavioral/electrocorticographic comparisons
  - diazepam
  - drug interactions
  - pentylentetrazol
  - Rat/rabbit comparisons, 115
  - analepsis
  - codeine
- Rate-decreasing effects, 569
  - cholecystokinin
  - dose-dependent effects
  - schedule-controlled behavior
- Rebound enhancement, 585
  - chronic administration
  - l-dopa
  - haloperidol
  - self-stimulation
- Receptor density, 325
  - dopamine D-1 receptors
  - dopamine D-2 receptors
  - receptor distribution
  - strain differences
- Receptor distribution, 325
  - dopamine D-1 receptors
  - dopamine D-2 receptors
  - receptor density
  - strain differences
- Receptor ligand binding, 169
  - chronic stress
  - [<sup>3</sup>H]cyclohexyladenosine
  - hypothalamus
- Reflex facilitation, 433
  - classical conditioning
  - CS-UCS interval
  - d-lysergic acid diethylamide
- Reinforcing effects, 227
  - drug self-administration
  - human studies
  - intravenous administration
  - nicotine
- Reinforcing properties, 195
  - brain-stimulation reward
  - buprenorphine
  - reward threshold
- Renin-angiotensin system, 823
  - alcohol intake
  - serotonin uptake inhibition
- Reproductive behavior, 729
  - aggressive behavior
  - alphaxalone
  - comparative effects
  - locomotor behavior
  - progesterone
- Response manipulandum, 879
  - four-drug discrimination
  - identical levers
- Restraint, 905
  - analgesia, morphine-induced
  - jumping, naloxone-induced
  - morphine
  - naloxone
- Retention, 949
  - acquisition
  - scopolamine
  - T-maze, 14-unit
- Retrieval, 1093
  - amnesia
  - scopolamine
- Reward effect, 657
  - GABA agonists
  - lateral hypothalamus
  - self-stimulation
- Reward threshold, 195
  - brain-stimulation reward
  - buprenorphine
  - reinforcing properties
- Rhesus monkeys, 493
  - N-allynormetazocine
  - oral self-administration
  - phencyclidine
  - withdrawal
- Rhythmic slow activity, 177
  - ethanol
  - hippocampus
  - strain differences
- Ritanserin, 853
  - d-amphetamine
  - conditioned place preference
  - diazepam
  - drug interactions
  - morphine
- RO 4-46202, 613
  - citalopram
  - discriminative stimulus
  - drug comparisons
  - l-5-hydroxytryptophan
- RO 5-4864, 749
  - central benzodiazepine agonist
  - clonazepam
  - drug comparisons
  - NaCl intake
  - peripheral benzodiazepine agonist
- [<sup>3</sup>H] RO 5-4864 binding, 1015
  - heart
  - kidney
  - peripheral benzodiazepine receptors
  - stress
- RO 15-4513
  - desipramine, 1045
  - differential sensitivity, 183
  - drug interactions, 501, 867
  - ethanol, 501, 867
  - ethanol antagonism, 183
  - ethanol intake, 1045
  - fluoxetine, 1045
  - food intake, 1045
- GABAergic system, 501
  - light/dark choice paradigm, 867
  - molecular interactions, 501
  - staircase test, 867
  - strain differences, 183, 1045
  - water intake, 1045
- Rotational behavior, 457
  - D<sub>1</sub>/D<sub>2</sub> agonists
  - dopamine
  - EEDQ
  - selective protection
- Route of administration, 309
  - amphetamine
  - cholecystokinin-octapeptide
  - hyperlocomotion
  - intra-accumbens injection
  - intracerebroventricular injection
  - stereotypy
- Salivary cotinine, 895
  - human studies
  - marijuana smoke
  - serum cotinine
  - tobacco smoke
- SCH 23390, 683
  - apomorphine
  - body temperature
  - haloperidol
- Schedule-controlled behavior, 569
  - cholecystokinin
  - dose-dependent effects
  - rate-decreasing effects
- Schedule-controlled performance, 1007
  - ionizing radiation
  - sublethal doses
- Schedule-induced wheel running, 101
  - adrenalectomy
  - corticosterone
- Scopolamine
  - acquisition, 949
  - amnesia, 1093
  - atropine, 625
  - chickens, 625
  - eight-arm radial maze, 119
  - immobility response, 625
  - nicotine, 119
  - paradoxical sleep suppression, 295
  - retention, 949
  - retrieval, 1093
  - SMS 201-995, 295
  - strain differences, 625
  - T-maze, 14-unit, 949
- Seizures, 665
  - benzodiazepine receptor binding
    - affinity
    - 3-hydroxykynurenine
    - neonatal deficiency
    - vitamin B-6
- Selective protection, 457
  - D<sub>1</sub>/D<sub>2</sub> agonists
  - dopamine
  - EEDQ
  - rotational behavior
- Self-stimulation
  - chronic administration, 515
  - cocaine, 1
  - l-dopa, 585
  - GABA agonists, 657
  - haloperidol, 585
  - imipramine, 1
  - interactive effects, 1
  - lateral hypothalamus, 657

- rebound enhancement, 585
- reward effect, 657
- train-duration thresholds, 1
- Self-stimulation reward, 589
  - catecholamines
  - drug interactions
  - endogenous opioids
  - ventral tegmental area
- Semicarbazide, 337
  - bicuculline
  - flight behavior
  - microinjection
  - rats, detelencephalated
- Serotonergic agonists, 617
  - discriminative stimulus
  - drug interactions
  - LSD
  - serotonergic antagonists
- Serotonergic antagonists, 617
  - discriminative stimulus
  - drug interactions
  - LSD
  - serotonergic agonists
- Serotonin, 37
  - drug interactions
  - lordosis
  - alpha-melanocyte stimulating hormone
- Serotonin metabolism, brain, 715
  - d-fenfluramine
  - uptake inhibition
- Serotonin receptors, 55
  - drug discrimination
  - drug interactions
  - dopamine receptors
  - ethanol
- Serotonin uptake, 847
  - behavioral effects
  - 5-methoxytryptamine
  - parachlorophenylalanine
  - prenatal exposure
- Serotonin uptake inhibitor, 823
  - alcohol intake
  - renin-angiotensin system
- Serum cotinine, 895
  - human studies
  - marijuana smoke
  - salivary cotinine
  - tobacco smoke
- Sex differences
  - analgesia, 123
  - drug-admixed food method, 483
  - methaqualone, 483
  - morphine, 123
  - physical dependence, 483
  - prenatal stress, 123
- Sexual behavior, 1021
  - rat, male
  - opioids
- Shock controllability, 209
  - chlordiazepoxide
  - contextual fear
  - nociception
- Shock-probe test, 1071
  - anxiolytics
  - bupirone
  - chlordiazepoxide
  - defensive burying
  - drug comparisons
- Short-term treatment, 889
  - imipramine
  - long-term treatment
- place preference, apomorphine-induced
- place preference, food-induced
- SKF 38393, 189
  - D1/D2 dopamine receptor stimulation
  - stereotyped behaviors
- Skin mucus, 957
  - escape
  - frogs
  - tardive dyskinesia
- Small groups, 539
  - human studies, males
  - marijuana
  - social behavior
- SMS 201-995, 295
  - paradoxical sleep suppression
  - scopolamine
- Social behavior, 539
  - human studies, males
  - marijuana
  - small groups
- Spatial learning, 519
  - Morris Water Maze
  - pirenzepine
- Spontaneous motor activity inhibition, 155
  - adenosine
  - cerebellum
  - ethanol
  - motor incoordination
- Staircase test, 867
  - drug interactions
  - ethanol
  - light/dark choice paradigm
  - RO 15-4513
- State-dependent memory, 83
  - human studies
  - nitrous oxide
- Stereotyped behavior
  - amphetamine, 899
  - chronic administration, 899
  - D1/D2 dopamine receptor stimulation, 189
  - SKF 38393, 189
- Stereotypy
  - amphetamine, 309, 535
  - cholecystokinin octapeptide, 309
  - circadian rhythm, 535
  - continuous administration, 535
  - hyperlocomotion, 309
  - intra-accumbens injection, 309
  - intracerebroventricular injection, 309
  - locomotor behavior, 535
  - route of administration, 309
- Stimulation reward, 365
  - dopamine
  - lateral hypothalamus
  - neonatal depletions
  - rats, adult
- Strain differences
  - acute administration, 769
  - acute pretreatment, 1065
  - adenosine receptors, 707
  - atropine, 625
  - autoradiography, 707, 781
  - brain regional uptake, 781
  - chickens, 625
  - 2-deoxyglucose, 781
  - desipramine, 1045
  - differential antagonism, 183
  - dopamine D-1 receptors, 325
  - dopamine D-2 receptors, 325
- ethanol, 177, 769, 781
- ethanol antagonism, 183
- ethanol intake, 1045
- fluoxetine, 1045
- food intake, 1045
- hippocampus, 177
- immobility response, 625
- methylxanthines, 707
- MHPG-SO<sub>2</sub>
- nicotine, 1065
- noradrenaline metabolism, 769
- plasma corticosterone levels, 1065
- receptor density, 325
- receptor distribution, 325
- rhythmic slow activity, 177
- RO 15-4513, 183, 1045
- scopolamine, 625
- water intake, 1045
- Stress, 1015
  - heart
  - kidney
  - peripheral benzodiazepine receptors
  - [<sup>3</sup>H] RO 5-4864 binding
- Structure-activity studies, 403
  - carbamate esters
  - nicotine
  - nicotine agonists
  - nicotine antagonists
- Sublethal doses, 1007
  - ionizing radiation
  - schedule-controlled performance
- Substantia innominata, 679
  - benzodiazepine binding sites
  - in vitro autoradiography
- Sulpiride, 917
  - drinking
  - eating
- Supraspinal cerebral areas, 319
  - analgesia
  - intestinal inhibition
  - morphine
- Tamoxifen, 829
  - aggressive behavior
  - medroxyprogesterone acetate
  - mice, male
- Tardive dyskinesia, 957
  - escape, 957
  - frogs
  - skin mucus
- T-cell antibody responses, 859
  - conditioned stimulus
  - cyclophosphamide
  - mice, female
  - unconditioned stimulus
- Thyrotropin-releasing hormone, 941
  - brain, rat
  - hypothermia
- Thyrotropin-releasing hormone binding, 73
  - behavioral effects
  - triazolobenzodiazepines
- T-maze, 14-unit, 949
  - acquisition
  - retention
  - scopolamine
- Tobacco dependence
  - human studies, 217
  - nicotine, 217
  - nicotine gum, 279
  - pharmacological effects, 217

- pharmacological treatment, 279
- Tobacco self-administration, 221
  - human studies
  - pharmacologic determinants
- Tobacco smoke, 895
  - human studies
  - marijuana smoke
  - salivary cotinine
  - serum cotinine
- Tolerance development, 755
  - amphetamine
  - anorectic effects
  - opiate mechanisms
  - U50488H
- Tonic component, 1001
  - benzodiazepines
  - postdecapitation convulsions
- Train-duration thresholds, 1
  - cocaine
  - imipramine
  - interactive effects
  - self-stimulation
- Triazolobenzodiazepines, 73
  - behavioral effects
  - thyrotropin-releasing hormone binding
- U50488H, 755
- amphetamine
  - anorectic effects
  - opiate mechanisms
  - tolerance development
- Unconditioned stimulus, 859
  - conditioned stimulus
  - cyclophosphamide
  - mice, female
  - T-cell antibody response
- Unpunished responding
  - apomorphine, 753
  - buspirone, 723
  - drug comparisons, 723
  - gepirone, 723
  - 8-hydroxy-2-(di-n-propylamino)tetralin, 723
  - pigeons, 723
  - punished responding, 753
- Uptake inhibition, 715
  - d-fenfluramine
  - serotonin metabolism, brain
- Ventral tegmental area, 589
  - catecholamines
  - drug interactions
  - endogenous opioids
  - self-stimulation reward
- Visceral cortex, 693
  - aversive effects
  - dopamine innervation
  - lesions, 6-OHDA
  - opiates
- Vitamin B-6, 665
  - benzodiazepine receptor binding
  - affinity
  - 3-hydroxykynurenine
  - neonatal deficiency
  - seizures
- Water intake, 1045
  - desipramine
  - ethanol intake
  - fluoxetine
  - food intake
  - RO 15-4513
  - strain differences
- Withdrawal, 493
  - N-allylnormetazocine
  - oral self-administration
  - phencyclidine
  - rhesus monkeys

## AUTHOR INDEX

- Abood, L. G., 403
- Agmo, A., 1021
- Aicher, S. A., 65
- Allen, J. L., 625
- Amir, S., 905
- Anderson, S. M., 169
- Artinián, J., 899
- Asin, K. E., 577
- Aulakh, C. S., 451
- Azar, A. P., 925
- Azmitia, E. C., 847
- Backus, L. I., 657
- Bagri, A., 337
- Baldwin, H. A., 809
- Barrett, J. E., 723
- Barthalmus, G. T., 957
- Basile, A. S., 1015
- Bassett, J. R., 391
- Bechara, A., 687, 693
- Bednarz, L. M., 189
- Belzung, C., 867
- Bendani, T., 397
- Beninger, R. J., 525
- Benowitz, N. L., 249
- Benson, R. W., 859
- Benvenga, M. J., 205
- Bernardis, L. L., 649
- Block, L. D., 665
- Boggan, W. O., 31
- Boja, J. W., 1085, 1089
- Bostwick, M., 255
- Boyd, S., 31
- Branch, M. N., 737
- Brandão, M., 337
- Bree, M. P., 977
- Bridges, R. S., 123
- Brooderson, R. J., 189
- Brown, R. L., 543
- Bruno, J. P., 365
- Cabib, S., 143, 765
- Calcagnetti, D. J., 817
- Calligaro, D., 163
- Campbell, I. C., 299, 347
- Cancela, L. M., 899
- Cappell, H., 515
- Carino, M. A., 115
- Carrive, P., 337
- Carroll, M. E., 493
- Cazala, P., 397
- Chachich, M. E., 949
- Chan, A. W. K., 385
- Chaturvedi, A. K., 1035
- Chinn, C., 115
- Chipkin, R. E., 683
- Choi, W. W., 83
- Clark, M., 155
- Clark, V. A., 895
- Co, C., 1051
- Collins, A. C., 269, 1059
- Compton, D. R., 371
- Cook, J. M., 243
- Cool-Hauser, V. A., 433
- Corrigall, W. A., 443, 787
- Coulaud, H., 89
- Craft, R. M., 775
- Cramer, C. P., 817
- Crawley, J. N., 129, 1015
- Cushing, L. L., 343
- D'Agata, V., 961
- Dall'olio, R., 463
- Danguir, J., 295
- Dar, M. S., 155
- De Robertis, E., 331
- De Saint-Hilaire-Kafi, S., 295
- Desan, P. H., 21, 563
- Domae, M., 1081
- Domer, F. R., 543
- Donzanti, B. A., 795
- Drago, F., 961
- Drugan, R. C., 1015
- Dunn, G., 299, 347
- Durcan, M. J., 299, 347
- Dworkin, S. I., 1051
- Dyer, R. S., 421
- Dymshitz, J., 905
- Edinger, H. M., 409
- Elgin, R. J., Jr., 137
- Engel, J. A., 471
- Ettenberg, A., 309
- Evans, R. L., 753
- Even, P., 89
- Falk, J. L., 749
- Fanselow, M. S., 817
- Faught, K., 31
- Feldman, M. J., 649
- Feldon, J., 871
- Fibiger, H. C., 835
- File, S. E., 809
- Fischman, M. W., 539
- Fleck-Kandath, C., 723
- Foltin, R. W., 539
- Fraile, I. G., 729
- Frampton, S. F., 417
- Frank, R. A., 1
- Franz, C. G., 1007
- Freedman, D. X., 427
- Freund, R. K., 1059
- Fulginiti, S., 899
- Fuller, R. W., 715
- Fundytus, M., 1071
- Furukawa, T., 1081
- Gähwiler, M., 199
- Gandolfi, O., 463
- Gatta, F., 5
- Gerhardt, G. A., 1077
- Geyer, M. A., 417
- Ghoneim, M. M., 83
- Giagnoni, G., 319
- Gianoulakis, C., 933
- Glennon, R. A., 597
- Goeders, N. E., 1051
- Gogas, K. R., 791
- Goldberg, S. R., 215, 217, 221, 227, 243
- Goodale, D. B., 457
- Gori, E., 319
- Gormezano, I., 433
- Grant, S. J., 13
- Gratton, A., 1077
- Greenblatt, D. J., 511
- Greenwood, C., 693
- Grinker, J. A., 925
- Grupp, L. A., 823
- Guerin, G. F., 1051
- Guilarte, T. R., 665
- Haertzen, C. A., 967
- Hagen, T. J., 243

- Hara, T., 1001  
Harding, J. W., 343  
Harrison, J. R., 1007  
Harvey, J. A., 433  
Hawkins, M., 303  
Hellevuo, K., 183  
Helmstetter, F. J., 817  
Hennig, C. W., 625  
Henningfield, J. E., 129, 217, 221, 227, 279  
Herberg, L. J., 585  
Hernandez, L., 917  
Herning, R. I., 129  
Hesse, G. W., 657  
Hill, J. L., 451  
Hiltunen, A. J., 675  
Hjorth, S., 189  
Hoebel, B. G., 917  
Hoffer, B. J., 1077  
Hollingsworth, E. M., 535  
Hook, R., 255  
Horita, A., 115  
Hough, L. B., 791  
Howard, J. L., 775  
Huang, Y. H., 13  
Hubner, C. B., 195  
Hunt, T., 515  
Hunter, A. J., 519  
Hutchison, W. D., 933
- Ichihara, K., 107  
Ida, Y., 769  
Ignatius, J., 177  
Inanaga, K., 769  
Ingram, D. K., 949  
Iwamoto, E. T., 119
- Jacob, J., 657  
Jacob, P., III, 249  
Jacobi, A. G. M., 457  
Järbe, T. U. C., 675  
Jarvik, J. E., 279  
Jarvis, M. F., 707  
Jasinski, D. R., 967  
Jensen, L. L., 343  
Johnson, R. E., 967  
Johnston, A. L., 809  
Judge, M. E., 77  
Jungschaffer, D. A., 1059
- Kaheinen, P., 177  
Kalant, H., 933  
Kalin, N. H., 801  
Kameyama, T., 107  
Kant, G. J., 169  
Katz, J. L., 243  
Kawazawa, S., 1001  
Kerr, L. M., 325  
Khazan, N., 163  
Kinsley, C. H., 123  
Klitenick, M. A., 577  
Kodis, M., 649  
Koike, Y., 483  
Kornetsky, C., 195  
Korpi, E. R., 177, 183, 781  
Korttila, K., 83  
Koshikawa, N., 347  
Kozlowski, M. R., 73  
Kulkarni, S. K., 501  
Kumor, K. M., 967  
Kuntz, D. J., 1035
- Langan, M. C., 385  
Leibowitz, S. F., 925  
Leidenheimer, N. J., 351  
Leo, P., 77, 1093  
Leong, F. W., 385  
Leu, J. R., 169  
Li, T.-K., 1045  
Lichtensteiger, W., 199  
Lin, W., 101  
Lindroos, F., 781  
Linseman, M. A., 787  
Lister, R. G., 701  
Long, R., 129  
Lopez, F., 511  
Lozada, M., 635  
Lubow, R. E., 871  
Lukas, S. E., 977  
Lumeng, L., 1045  
Lyddane, J. E., 371  
Lyon, R. A., 597
- McBride, W. J., 1045  
McEwen, B. S., 729  
McEwen, G., 649  
McIntire, K. D., 45  
McIntyre, J. F., 625  
McIntyre, T., 911  
McMillan, D. E., 753  
McNicholas, L. F., 945  
McWilliam, J. R., 299
- Maier, S. F., 21, 563  
Maiti, A., 403  
Maldonado, H., 635  
Mann, P. E., 123  
Mansbach, R. S., 723  
Mantysalo, S., 177  
Marks, M. J., 269  
Martin, B. J., 1059, 1065  
Martin, B. R., 371  
Martin, G. E., 137  
Martin, G. M., 687  
Martin, W. R., 255, 945  
Martin-Iverson, M. T., 835  
Massi, P., 319  
Massotti, M., 5  
Matsumoto, S., 1081  
Matsuo, N., 1081  
Matthews, A., 543  
Mazurski, E. J., 525  
Medina, J. H., 331  
Mehrabani, P. A., 391  
Mehta, A. K., 995  
Mele, L., 5  
Mele, P. C., 1007  
Mello, N. K., 977  
Mendelson, J. H., 977  
Mewaldt, S. P., 83  
Middaugh, L. D., 31  
Miller, L. G., 511  
Miner, L. L., 269  
Mintz, M., 585  
Misawa, M., 483  
Misslin, R., 867  
Miyazaki, M., 941  
Mizobe, T., 941  
Mizuki, Y., 1001  
Montanaro, N., 463  
Moriarty, D. D., Jr., 625  
Mueller, K., 535  
Munday, W. R., 119
- Murphy, D. L., 451  
Murphy, J. M., 1045  
Muscat, R., 641
- Nabeshima, T., 107  
Neale, M. C., 299  
Nencini, P., 755  
Nicolaidis, S., 89  
Nitz, D., 1  
Nomikos, G. G., 853  
Novas, M. L., 331
- Oguchi, M., 769  
Okuda, C., 941  
Overton, D. A., 879
- Papasava, M., 101  
Papp, M., 889  
Pappas, B. A., 479  
Parada, M. A., 917  
Paredes, R., 1021  
Parolaro, D., 319  
Patrini, G., 319  
Paul, S. M., 511, 1015  
Paule, M. G., 859  
Penetrante, M. L., 385  
Perlanski, E., 823  
Perry, M., 829  
Peters, D. A. V., 669  
Petersen, R. C., 83  
Pfaff, D. W., 729  
Picerno, J. M., 625  
Picker, M., 603  
Pickworth, W. B., 129  
Pisa, M., 835  
Plaessmann, W. R., 749  
Pollard, G. T., 775  
Pommering, T., 1  
Poulos, C. X., 515  
Pravica, M., 303  
Puglisi-Allegra, S., 143, 765  
Pyykko, I., 177
- Quartermain, D., 77, 1093
- Rabin, R. A., 613, 617  
Radulovacki, M., 303  
Raible, L., 37  
Randich, A., 65  
Redmond, D. E., Jr., 13  
Ribary, U., 199  
Rigdon, G. C., 421  
Riley, A. L., 569  
Roberts, D. W., 859  
Roberts, F. F., 519  
Robertson, D. W., 715  
Romano, A., 635  
Roncada, P., 463  
Rose, I. C., 585  
Rosellini, R. A., 209  
Ryan, C. L., 479  
Ryan, S. M., 563
- Sahid Salles, K., 403  
Sala, M., 319  
Sarter, M., 679  
Satoh, H., 769  
Scalisi, B., 961  
Scapagnini, U., 961  
Schanley, D. L., 385  
Schechter, M. D., 55, 351, 1085, 1089
- Schindler, C. W., 433  
Schlumpf, M., 199  
Schmitt, P., 337  
Schneider, H. H., 679  
Schulze, G. E., 859  
Seifert, W. F., 589  
Seran, G. F., 357  
Seyfried, D. M., 457  
Shader, R. I., 511  
Shaikh, M. B., 409  
Shashoua, V. E., 657  
Shemer, A., 847  
Shen, C. F., 879  
Sherman, J. E., 801  
Shirakawa, K., 1081  
Shirao, I., 769  
Shor-Posner, G., 925  
Shreve, P. E., 379  
Shulgin, A. T., 249  
Siegel, A., 409  
Siegel, S., 427  
Signs, S. A., 55  
Silbert, L. H., 21  
Simmons, M., 895  
Simon, N. G., 829  
Singer, G., 101  
Sizemore, G. M., 737  
Skirboll, L. R., 129  
Skolnick, P., 911, 1015  
Sloan, J. W., 255, 945  
Smith, J. E., 1051  
Smock, T. K., 563  
Smythe, J. W., 479  
Snoddy, H. D., 715  
Söderpalm, B., 471  
Spangler, E. L., 949  
Sparber, S. B., 357  
Spaulding, T. C., 205  
Spyraki, C., 853  
Stein, E. A., 983  
Stellar, J. R., 365, 657  
Stewart, R. B., 823  
Stivers, J. A., 129  
Stolerman, I. P., 235  
Suzuki, T., 483
- Takada, K., 243  
Tanaka, M., 769  
Tang, M., 749  
Tanzer, D. J., 309  
Tashkin, D. P., 895  
Thomas, B. F., 371  
Ticku, M. K., 501, 995  
Titeler, M., 597  
Tomaz, C., 337  
Towell, A., 641  
Treit, D., 1071  
Trifunovic, R., 529  
Trullas, R., 911  
Trusk, T. C., 983  
Tsuda, A., 769  
Tsujiyama, S., 769
- Ullman, E. A., 1059  
Unis, A. S., 325  
Uretsky, N. J., 379  
Ushijima, I., 1001
- Vaccarino, F. J., 443  
Vaccheri, A., 463  
Valerio, C., 961



van der Kooy, D., 687, 693  
Van Ree, J. M., 589  
Van Vunakis, H., 895  
Van Wolfswinkel, L., 589  
Vogel, E., 867  
Volpe, M., 925  
  
Wachtel, S. R., 189  
Wagner, H. N., Jr., 665  
Wala, E., 255, 945  
  
Wamsley, J. K., 325  
Wängdahl, K., 675  
Waraczynski, M., 365  
Warren, D. A., 209  
Wehner, J. M., 1065  
Weiner, I., 871  
Weiss, B., 457  
Weiss, F., 309  
Wessler, G., 543  
Whitaker-Azmitia, P. M., 847  
  
White, F. J., 189  
Wilks, L. J., 809  
Williams, M., 707  
Willner, P., 641  
Winsauer, P. J., 569  
Winter, J. C., 613, 617  
Wirtshafter, D., 529, 577  
Wise, R. A., 1077  
Wolfman, C., 331  
Woodmansee, W. W., 563  
  
Wozniak, K. M., 451  
Wright, J. W., 343  
  
Yamada, K., 1081  
Yamada, M., 1001  
Yamamoto, B. K., 795  
Young, G. A., 163, 489  
  
Zielinski, W. J., 957  
Zito, K. A., 693